Clinical trial · Interventional
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
NCT01699581CI-TRIAL-00024329terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Research cancelled following interim analysis
Summary
Brief summary (as posted)
Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin's Lymphoma | Hodgkin Lymphoma | ALIAS | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nestle Impact Advanced Recovery | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Nestle Impact Advanced Recovery
- description
- Nestle Impact Advanced Recovery 1 dose of Nestle Impact Advanced Recovery orally three times a day
- interventionNames
- Dietary Supplement: Nestle Impact Advanced Recovery
Primary outcomes (2)
- measure
- Hospital length of stay
- timeFrame
- Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge
- measure
- Days to engraftment
- timeFrame
- Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2 * Any prior diet or supplement will be allowed. * Age \>18 years. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nestle Impact including fish oil.
References
Publications (0)
Data not yet available
No reference posted for this study.